Trial Profile
Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Biomarker; Therapeutic Use
- Acronyms STIM-2
- 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 12 Mar 2018 Status changed from active, no longer recruiting to completed.
- 22 Jul 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.